DLTNF logo

Delta 9 Cannabis Inc. (DLTNF)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Mit einem Kurs von $ ist Delta 9 Cannabis Inc. (DLTNF) ein Healthcare-Unternehmen mit einer Bewertung von 0. Bewertet mit 42/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 16. März 2026
42/100 KI-Bewertung

Delta 9 Cannabis Inc. (DLTNF) Gesundheitswesen & Pipeline-Uebersicht

CEOJohn William Arbuthnot IV
Mitarbeiter200
HauptsitzWinnipeg, CA
IPO-Jahr2017

Delta 9 Cannabis Inc. is a Canadian integrated cannabis company involved in cultivation, processing, distribution, and retail. With 35 retail stores across the Canadian Prairies, Delta 9 offers a range of cannabis products, including dried flowers, oils, and derivative products, catering to both medical and recreational markets.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 16. März 2026

Investmentthese

Delta 9 Cannabis Inc. presents a speculative investment opportunity in the evolving Canadian cannabis market. The company's integrated business model, encompassing cultivation, processing, distribution, and retail, offers potential for revenue generation across the value chain. However, with a negative profit margin of -24.6% and a negative gross margin of -3.4%, the company's profitability is a concern. Future growth hinges on expanding retail operations, optimizing production costs, and capitalizing on emerging cannabis product trends. Investors should closely monitor the company's ability to achieve profitability and navigate the competitive landscape. The company's P/E ratio is -0.05.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Delta 9 Cannabis Inc. operates as an integrated cannabis company, participating in cultivation, processing, distribution, and retail sales.
  • The company owns and operates 35 retail stores under the Delta 9 brand name across the Canadian Prairies as of April 20, 2022.
  • Delta 9's product portfolio includes dried cannabis flowers, pre-rolls, oils, and extracted products, catering to both medical and recreational markets.
  • The company has a negative profit margin of -24.6% and a negative gross margin of -3.4%, indicating profitability challenges.
  • Delta 9's beta of 1.13 suggests that the stock is more volatile than the market average.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Integrated operations across the cannabis value chain.
  • Established retail presence in the Canadian Prairies.
  • Proprietary grow pod technology.
  • Delta 9 brand recognition.

Schwaechen

  • Negative profit margin and gross margin.
  • Limited geographic presence compared to larger competitors.
  • Reliance on the Canadian cannabis market.
  • Small market capitalization.

Katalysatoren

  • Ongoing: Expansion of retail operations to new locations.
  • Ongoing: Development and launch of new cannabis products.
  • Ongoing: Potential changes in cannabis regulations in Canada.
  • Upcoming: Announcement of strategic partnerships or acquisitions.
  • Upcoming: Positive financial results demonstrating improved profitability.

Risiken

  • Ongoing: Intense competition in the Canadian cannabis market.
  • Ongoing: Evolving regulations and compliance requirements.
  • Potential: Fluctuations in cannabis prices affecting revenue.
  • Potential: Economic downturn reducing consumer spending on cannabis.
  • Potential: Delays in regulatory approvals for new products or expansion plans.

Wachstumschancen

  • Expansion of Retail Footprint: Delta 9 can expand its retail presence beyond the Canadian Prairies to other provinces, increasing its market reach and revenue potential. The Canadian cannabis retail market is projected to reach several billion dollars in the coming years, offering significant growth opportunities for companies with established retail networks. The timeline for expansion depends on regulatory approvals and capital availability.
  • Product Innovation and Diversification: Delta 9 can invest in research and development to create new and innovative cannabis products, catering to evolving consumer preferences. This includes developing new formulations, delivery methods, and product formats. The market for cannabis-infused products, such as edibles and beverages, is growing rapidly, presenting opportunities for Delta 9 to diversify its product portfolio. The timeline for product development and launch is typically 12-18 months.
  • Strategic Partnerships and Acquisitions: Delta 9 can pursue strategic partnerships and acquisitions to expand its capabilities and market reach. This includes partnering with other cannabis companies, technology providers, or research institutions. Acquisitions can provide access to new markets, technologies, or product lines. The timeline for partnerships and acquisitions varies depending on the specific opportunities.
  • International Expansion: Delta 9 can explore opportunities to expand its operations internationally, particularly in countries with legal cannabis markets. This includes exporting cannabis products, establishing joint ventures, or acquiring foreign cannabis companies. The global cannabis market is growing rapidly, offering significant long-term growth potential. The timeline for international expansion depends on regulatory approvals and market conditions.
  • Medical Cannabis Focus: Delta 9 can focus on expanding its medical cannabis business, catering to patients seeking cannabis-based therapies. This includes developing new medical cannabis products, partnering with healthcare providers, and conducting clinical research. The medical cannabis market is growing steadily, driven by increasing awareness of the therapeutic benefits of cannabis. The timeline for medical cannabis initiatives depends on regulatory approvals and clinical trial results.

Chancen

  • Expansion of retail footprint to other provinces.
  • Product innovation and diversification.
  • Strategic partnerships and acquisitions.
  • International expansion.

Risiken

  • Increasing competition in the Canadian cannabis market.
  • Evolving regulations and compliance requirements.
  • Fluctuations in cannabis prices.
  • Economic downturn affecting consumer spending.

Wettbewerbsvorteile

  • Integrated operations provide control over the entire value chain.
  • Established retail presence in the Canadian Prairies.
  • Proprietary grow pod technology.
  • Delta 9 brand recognition.

Ueber DLTNF

Delta 9 Cannabis Inc., incorporated in 2001 and headquartered in Winnipeg, Canada, operates as an integrated cannabis company. Through its subsidiary, Delta 9 Bio-Tech Inc., the company cultivates, processes, extracts, and distributes cannabis products. Delta 9's operations span the entire cannabis value chain, from cultivation to retail sales. The company's product portfolio includes dried cannabis flowers, pre-rolls, decontamination pods, dried sift cannabis, oils, and extracted and derivative products. Delta 9 also provides grow pods and live plants to other licensed and pre-licensed cannabis companies. In addition to its product offerings, Delta 9 operates a medical clinic providing physician consultation services for patients seeking medical cannabis prescriptions. As of April 20, 2022, Delta 9 owned and operated 35 retail stores under the Delta 9 brand name across the Canadian Prairies, solidifying its presence in the regional cannabis market. Delta 9 continues to expand its retail footprint and product offerings to meet the evolving demands of the cannabis market.

Was das Unternehmen tut

  • Cultivates cannabis plants in controlled environments.
  • Processes raw cannabis into various product forms.
  • Extracts cannabinoids to create oils and concentrates.
  • Wholesales cannabis products to other licensed retailers.
  • Operates retail stores under the Delta 9 brand.
  • Sells medical and recreational cannabis products.
  • Provides physician consultation services for medical cannabis prescriptions.

Geschaeftsmodell

  • Vertically integrated operations from cultivation to retail.
  • Revenue generation through wholesale and retail sales of cannabis products.
  • Medical clinic services providing cannabis prescriptions.
  • Sales of grow pods and live plants to other licensed producers.

Branchenkontext

Delta 9 Cannabis Inc. operates within the rapidly evolving Canadian cannabis industry. The market is characterized by increasing competition, evolving regulations, and shifting consumer preferences. Delta 9 competes with other licensed producers and retailers, vying for market share in both the medical and recreational cannabis segments. The Canadian cannabis market is expected to continue growing, driven by increasing legalization and acceptance of cannabis products. Companies like Delta 9 must adapt to changing regulations and consumer demands to remain competitive.

Wichtige Kunden

  • Recreational cannabis consumers.
  • Medical cannabis patients with prescriptions.
  • Other licensed cannabis retailers (wholesale).
  • Licensed and pre-licensed cannabis companies (grow pods and live plants).
KI-Zuversicht: 71% Aktualisiert: 16. März 2026

Finanzdaten

Chart & Info

Delta 9 Cannabis Inc. (DLTNF) Aktienkurs: Price data unavailable

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer DLTNF.

Kursziele

Wall-Street-Kurszielanalyse fuer DLTNF.

MoonshotScore

42/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von DLTNF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Fuehrung: John William Arbuthnot IV

CEO

John William Arbuthnot IV serves as the CEO of Delta 9 Cannabis Inc. His leadership is pivotal in guiding the company's strategic direction and operational execution. Information regarding his specific educational background and previous roles is not available. As CEO, he is responsible for overseeing all aspects of the company's operations, including cultivation, processing, distribution, and retail sales. He manages a workforce of approximately 200 employees.

Erfolgsbilanz: Under John William Arbuthnot IV's leadership, Delta 9 Cannabis Inc. has expanded its retail footprint to 35 stores across the Canadian Prairies. He has overseen the development and launch of new cannabis products and the implementation of the company's integrated business model. However, the company's financial performance has been challenged by negative profit margins.

DLTNF OTC-Marktinformationen

The OTC Other tier represents the lowest tier of the OTC market, indicating that Delta 9 Cannabis Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.

  • OTC-Stufe: OTC Other
  • Offenlegungsstatus: Unknown
Liquiditaet: As an OTC-listed stock, DLTNF may experience lower trading volumes and wider bid-ask spreads compared to stocks listed on major exchanges. This can make it more difficult to buy or sell shares quickly and at desired prices. Investors should be aware of the potential for price volatility and illiquidity when trading DLTNF.
OTC-Risikofaktoren:
  • Limited financial disclosure and transparency.
  • Lower trading volumes and liquidity.
  • Potential for price volatility.
  • Higher risk of fraud or manipulation.
  • Limited regulatory oversight.
Sorgfaltspruefung-Checkliste:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the company's management team and their track record.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's regulatory compliance and legal risks.
  • Monitor trading volumes and price movements.
  • Consult with a financial advisor.
  • Understand the risks associated with OTC investing.
Legitimitaetssignale:
  • Licensed cannabis producer and retailer in Canada.
  • Operational retail stores under the Delta 9 brand.
  • Presence in the cannabis industry since 2001.
  • Integrated operations across the cannabis value chain.

Haeufige Fragen zu DLTNF

What are the key factors to evaluate for DLTNF?

Delta 9 Cannabis Inc. (DLTNF) currently holds an AI score of 42/100, indicating low score. Key strength: Integrated operations across the cannabis value chain.. Primary risk to monitor: Ongoing: Intense competition in the Canadian cannabis market.. This is not financial advice.

How frequently does DLTNF data refresh on this page?

DLTNF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven DLTNF's recent stock price performance?

Recent price movement in Delta 9 Cannabis Inc. (DLTNF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Integrated operations across the cannabis value chain.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider DLTNF overvalued or undervalued right now?

Determining whether Delta 9 Cannabis Inc. (DLTNF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying DLTNF?

Before investing in Delta 9 Cannabis Inc. (DLTNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding DLTNF to a portfolio?

Potential reasons to consider Delta 9 Cannabis Inc. (DLTNF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Integrated operations across the cannabis value chain.. Additionally: Established retail presence in the Canadian Prairies.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of DLTNF?

Yes, most major brokerages offer fractional shares of Delta 9 Cannabis Inc. (DLTNF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track DLTNF's earnings and financial reports?

Delta 9 Cannabis Inc. (DLTNF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for DLTNF earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Financial data is limited.
  • OTC stocks are inherently riskier than exchange-listed stocks.
Datenquellen

Popular Stocks